IL-17A/F inhibitor bimekizumab shows higher response and maintenance rates compared with secukinumab

An analysis of the long-term efficacy of bimekizumab versus secukinumab found greater proportions of response and maintenance for the IL17A/F inhibitor. In the phase 3b BE RADIANT trial, 88.0% of bimekizumab and 79.1% of secukinumab responders reaching a Psoriasis Area and Severity Index (PASI) ≤2 at week 16 upheld response to week 48.

Data obtained from psoriatic patients has revealed that not only the achievement of clear or almost clear skin is very important, but also the durability of the therapy effect [1,2]. With this in mind, a post-hoc analysis of the phase 3b, head-to-head BE RADIANT trial (NCT03536884) was performed, which evaluated participants achieving a PASI ≤2 or 0 on bimekizumab or secukinumab at week 16 in their ability to maintain the response continuously through week 48 [3].

After randomisation, 743 trial participants received either 320 mg of bimekizumab 4- or 8-weekly or 300 mg of secukinumab every week until week 4 and every 4 weeks thereafter. Overall, baseline characteristics were evenly distributed except for the severity of psoriasis, noted as a higher percentage of Investigator’s Global Assessment (IGA) scale 4 in the bimekizumab arm (35.1%) versus the secukinumab group (27.6%).

Study results at week 16 revealed an achievement of PASI 0 in 61.7% in the bimekizumab arm and 48.9% in the secukinumab arm, whereas PASI ≤2 was found in 85.3% and 76.5%, respectively. Comparing the maintenance rates, 63.7% of participants on bimekizumab and 54.3% of those on secukinumab were able to retain PASI 0. A continuance of PASI ≤2 response from week 16 to 48 was detected in 88% of the bimekizumab and 79.1% of the secukinumab group. Of note, 93% (bimekizumab) and 87.4% (secukinumab) of study participants who started with a PASI 0 at week 16 held up a PASI ≤2 through to week 48.

So, in conclusion, the higher percentages of bimekizumab-treated participants reaching PASI 0 or ≤2 at week 16 versus those in the secukinumab arm were perpetuated into higher rates of continuous maintenance of response with ongoing treatment up to 48 weeks.

1. Rasmussen MK, et al. Acta Derm Venereol. 2019;99:158-63.
2. Tada Y, et al. J Dermatol. 2021;48:1665-74.
3. Warren RB, et al. Bimekizumab versus Secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: post-hoc results from BE RADIANT phase 3B trial. P072, SPIN 2022 Congress, 06–08 July, Paris, France.

 

Copyright ©2022 Medicom Medical Publishers



Posted on 26 August 2022